UK +44 (0)1865 849841
Malaysia +603 2779 0098

Submission-ready microbiome data for clinical trials

Enabled by clonal-level microbiome profiling engraftment analysis, metabolomics and multi-omics analysis

The Microbiome & Probiotics R&D and Business Collaboration Forum recently hosted Marianne Koliana, VP of Business Development at Clinical Microbiomics. In the presentation she delved into crucial aspects of clinical trials, including regulatory compliance, engraftment analysis, and the pivotal role of multi-omics approaches, offering a comprehensive understanding of the evolving field.

Read More

Unravelling the Complexity of NAFLD: Insights from Professor Chris Byrne’s Presentation at the Global NASH Congress

The 6th Global NASH Congress in London witnessed an enlightening presentation by Professor Chris Byrne, a distinguished metabolic physician and endocrinologist. His comprehensive exploration of non-alcoholic fatty liver disease (NAFLD) unveiled its intricate nature as a multisystem disorder. This blog post aims to delve deeper into the key insights shared by Professor Byrne, elaborating on the relationship between NAFLD and type 2 diabetes, the significance of diagnosing NAFLD in patients living with diabetes, the potential benefits of PPAR gamma agonists, and the amplified risk of extrahepatic complications in NAFLD when people have type 2 diabetes.

Read More

Advancement in Therapeutics: Anti-Obesity Medications

Scott Harris, the Chief Medical Officer of Altimmune, gave a keynote address at the 6th Global NASH Congress where he discussed the development of drugs for both obesity and the treatment of NASH. He began by describing the statistics on obesity in the US and the lack of effective and safe therapies for the treatment of obesity in the past. He then highlighted the recent breakthroughs in incretin-based therapies, such as GLP-1, GLP-1/GIP, and GLP-1/glucagon dual agonists, which have shown promising results in clinical trials.

Read More

Digital pathology and service design

Digital health solutions in general have a poor track record of being sustained once they are implemented, often resulting in abandonment of the technology. Current digital pathology and artificial intelligence (AI) deployment strategies are generally too IT-focused – the technology being the focus, rather than the people and environment into which they are being deployed. Furthermore, a focus on technology alone will also hamper the effective integration of AI tools into the diagnostic workflow.

Read More

Discovering event sustainability in Brussels

“Our biggest challenge in this new century is to take an idea that seems abstract – sustainable development – and turn it into a reality ”

Kofi Annan

To try and turn that abstract idea into something more tangible, Global Engage has joined ISLA. This is a body that is working with the events industry to accelerate its transition to a sustainable future.

Read More

Switch to digital pathology bears fruit

Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.

Prof Alexi Baidoshvili

Read More

What is Net Zero and what does it mean for events?

As the world considers how it can mitigate climate change, Global Engage has committed to playing its part by reducing the impact of running events. But how to do it? I recently attended an onboarding course organised by ISLA and discovered that “Carbon Neutral” and “Net Zero” are not the same thing!

Read More

Digital Pathology: The Next Hurdles

A Market on the Rise
There has clearly been a surge in interest for digital pathology adoption over the last two years

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.